ArticleCurrent cardiovascular risk reports2019
The Use of Risk Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-society Cholesterol Guidelines.
Article in Current cardiovascular risk reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Prevalence of Atherosclerotic Cardiovascular Disease Risk-Enhancing Factors and Their Association with Primary Prevention Statin Use.Journal of general internal medicine · 2026Article
- Recalibrating Risk: A Call for South Asian-Focused Heart Failure Prediction Models.Journal of clinical medicine · 2026Review
- The ABCs of cardiovascular disease prevention: communicating what we know in 2026.American journal of preventive cardiology · 2026Review
- Atherosclerotic Cardiovascular Disease Risk Estimates Using the New Predicting Risk of Cardiovascular Disease Events Equations: Implications for Statin Use.Current cardiology reports · 2025Review
- Integrated Multivariate Predictive Model of Body Composition and Lipid Profile for Cardiovascular Risk Assessment.Journal of clinical medicine · 2025Article
- A 10-Year Risk Assessment and Primary Prevention Study of Atherosclerotic Cardiovascular Disease Among Adult Patients in Saudi Arabia: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2025Article
- The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.American journal of preventive cardiology · 2024Article
- Leveling the playing field: The utility of coronary artery calcium scoring in cardiovascular risk stratification in South Asians.American journal of preventive cardiology · 2023Review
- Utility of coronary artery calcium in refining 10-year ASCVD risk prediction using a Thai CV risk score.Frontiers in cardiovascular medicine · 2023Article
- Coronary Artery Restenosis in Women by History of Preeclampsia.Journal of the American Heart Association · 2022Article
- Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices.Preventive medicine reports · 2022Review
- Evaluation and management of blood lipids through a woman's life cycle.American journal of preventive cardiology · 2022Review
- Sex-Specific Considerations in the Presentation, Diagnosis, and Management of Ischemic Heart Disease: JACC Focus Seminar 2/7.Journal of the American College of Cardiology · 2022Review
- Machine learning derived ECG risk score improves cardiovascular risk assessment in conjunction with coronary artery calcium scoring.Frontiers in cardiovascular medicine · 2022Article
- Review
- Emerging Strategies for the Management of Atherogenic Dyslipidaemia.European cardiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
purpose of reviewIn 2018, the AHA/ACC multi-society Cholesterol Guidelines introduced the novel concept of risk-enhancing factors to be used as a supplement to the pooled cohort risk equations to personalize atherosclerotic cardiovascular disease risk assessment in primary prevention. In this review, we discuss the rationale and evidence behind each of the risk- enhancing factors to help clinicians perform a more personalized cardiovascular risk assessment. RECENT
findingsThe risk-enhancing factors are high-risk features that may guide the use of lipid-lowering therapy particularly in intermediate and select borderline risk patients. For the purpose of this review, these factors are divided into 5 categories: (i) race and genetics, (ii) conditions specific to women (iii) lipid related risk, (iv) concurrent high-risk medical conditions, and (v) biomarkers. SUMMARY: The addition of the risk-enhancing factors to the pooled cohort equations provides a more individualized and comprehensive approach to cardiovascular disease risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.